211 related articles for article (PubMed ID: 32006609)
1. MRI-Guided Ultrafocal Salvage High-Dose-Rate Brachytherapy for Localized Radiorecurrent Prostate Cancer: Updated Results of 50 Patients.
van Son MJ; Peters M; Moerland MA; Lagendijk JJW; Eppinga WSC; Shah TT; Ahmed HU; van der Voort van Zyp JRN
Int J Radiat Oncol Biol Phys; 2020 May; 107(1):126-135. PubMed ID: 32006609
[TBL] [Abstract][Full Text] [Related]
2. MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study.
Peters M; van Son MJ; Moerland MA; Kerkmeijer LGW; Eppinga WSC; Meijer RP; Lagendijk JJW; Shah TT; Ahmed HU; van der Voort van Zijp JRN
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1045-1053. PubMed ID: 30926575
[TBL] [Abstract][Full Text] [Related]
3. Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer.
Maenhout M; Peters M; van Vulpen M; Moerland MA; Meijer RP; van den Bosch MAAJ; Nguyen PL; Frank SJ; van der Voort van Zyp JRN
Technol Cancer Res Treat; 2017 Dec; 16(6):1194-1201. PubMed ID: 29333958
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
Hsu CC; Hsu H; Pickett B; Crehange G; Hsu IC; Dea R; Weinberg V; Gottschalk AR; Kurhanewicz J; Shinohara K; Roach M
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):370-7. PubMed ID: 22672747
[TBL] [Abstract][Full Text] [Related]
5. MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life.
Maenhout M; Peters M; Moerland MA; Meijer RP; van den Bosch MAAJ; Frank SJ; Nguyen PL; van Vulpen M; van der Voort van Zyp JRN
Radiother Oncol; 2018 Dec; 129(3):554-560. PubMed ID: 30131183
[TBL] [Abstract][Full Text] [Related]
6. A Prospective Study of Magnetic Resonance Imaging-guided Focal Salvage High-dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: Updated Results of 30 Patients.
Corkum MT; Morton G; Loblaw DA; Tseng CL; Murgic J; Ravi A; Davidson MTM; Wronski M; Haider M; Chung HT
Pract Radiat Oncol; 2022; 12(6):e531-e537. PubMed ID: 35718075
[TBL] [Abstract][Full Text] [Related]
7. F-SHARP: a Phase I/II trial of focal salvage high-dose-rate brachytherapy for Radiorecurrent prostate cancer.
Solanki AA; Yoo RK; Adams W; Davicioni E; Mysz ML; Shea S; Gupta GN; Showalter T; Garant A; Hentz C; Farooq A; Baldea K; Small W; Harkenrider MM
BJU Int; 2024 Feb; 133(2):188-196. PubMed ID: 37562825
[TBL] [Abstract][Full Text] [Related]
8. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
9. Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life.
Peters M; Maenhout M; van der Voort van Zyp JR; Moerland MA; Moman MR; Steuten LM; van Deursen MJ; van Vulpen M
Radiother Oncol; 2014 Jul; 112(1):77-82. PubMed ID: 24998704
[TBL] [Abstract][Full Text] [Related]
10. Protocol-based image-guided salvage brachytherapy. Early results in patients with local failure of prostate cancer after radiation therapy.
Lahmer G; Lotter M; Kreppner S; Fietkau R; Strnad V
Strahlenther Onkol; 2013 Aug; 189(8):668-74. PubMed ID: 23824103
[TBL] [Abstract][Full Text] [Related]
11. Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer.
Siddiqui ZA; Gustafson GS; Ye H; Martinez AA; Mitchell B; Sebastian E; Limbacher A; Krauss DJ
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1038-1044. PubMed ID: 30771408
[TBL] [Abstract][Full Text] [Related]
12. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
[TBL] [Abstract][Full Text] [Related]
13. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
[TBL] [Abstract][Full Text] [Related]
14. Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity.
Henríquez I; Sancho G; Hervás A; Guix B; Pera J; Gutierrez C; Abuchaibe O; Martínez-Monge R; Tormo A; Polo A
Radiat Oncol; 2014 Apr; 9():102. PubMed ID: 24885287
[TBL] [Abstract][Full Text] [Related]
15. Development and internal validation of prediction models for biochemical failure and composite failure after focal salvage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient prognoses.
Peters M; Kanthabalan A; Shah TT; McCartan N; Moore CM; Arya M; van der Voort van Zyp JR; Moerland MA; Hindley RG; Emberton M; Ahmed HU
Urol Oncol; 2018 Jan; 36(1):13.e1-13.e10. PubMed ID: 28927782
[TBL] [Abstract][Full Text] [Related]
16. Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome.
Jiang P; van der Horst C; Kimmig B; Zinsser F; Poppe B; Luetzen U; Juenemann KP; Dunst J; Siebert FA
Brachytherapy; 2017; 16(1):186-192. PubMed ID: 28341011
[TBL] [Abstract][Full Text] [Related]
17. Salvage Stereotactic Body Radiation Therapy for Local Prostate Cancer Recurrence After Radiation Therapy: A Retrospective Multicenter Study of the GETUG.
Pasquier D; Martinage G; Janoray G; Rojas DP; Zerini D; Goupy F; De Crevoisier R; Bogart E; Calais G; Toledano A; Chauveinc L; Scher N; Bondiau PY; Hannoun-Levi JM; Silva M; Meyer E; Nickers P; Lacornerie T; Jereczek-Fossa BA; Lartigau E
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):727-734. PubMed ID: 31344433
[TBL] [Abstract][Full Text] [Related]
18. Fractionated perineal high-dose-rate temporary brachytherapy combined with external beam radiation in the treatment of localized prostate cancer: is lymph node sampling necessary?
Kovács G; Galalae R
Cancer Radiother; 2003 Apr; 7(2):100-6. PubMed ID: 12719039
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of magnetic resonance imaging-ultrasound guided high-dose-rate brachytherapy for localized prostate cancer: Preliminary results from a prospective study.
Kamitani N; Miyaji Y; Tamada T; Yoden E; Kawata Y; Watanabe K; Tokiya R; Nagai A; Katsui K
Int J Urol; 2022 Jul; 29(7):725-732. PubMed ID: 35355325
[TBL] [Abstract][Full Text] [Related]
20. Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer.
Chitmanee P; Tsang Y; Tharmalingam H; Hamada M; Alonzi R; Ostler P; Hughes R; Lowe G; Hoskin P
Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):259-265. PubMed ID: 31708350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
